



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY



**Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

Tamil Nadu Medical & Pediatric Oncologist Society (TAMPOS) Conference

20th to 22nd March 2026 | Le Méridien Coimbatore

Program Directors: Dr. Vignesh Kanda Kumar, Dr. Ram Abhinav K & Dr. Ram Kumar M

Day 1 | 20th March 2026 | Friday | Hall A

9:00 am onwards	Breakfast and Registration	
9:30 am to 10:30 am	<p>Prelims for TAMPOS Gold Medal Exam Coordinators: Dr. Krishna Kumar Rathnam, Dr. S Krupa Shankar, Dr. PK Jayachandran & Dr. Kiran Kumar DVS Examiners: Dr. PN Sathiyamoorthy, Dr. Prabagar Manickam, Dr. Venkatraman Radhakrishnan & Dr. J Kannan</p>	
10:30 am to 10:50 am	<p><i>Sponsored Session (Astellas)</i> Enfortumab Vedotin in Relapsed/ Refractory Bladder Cancer Speaker: Dr. Rejiv Rajendranath</p>	
10:50 am to 11:20 am	<p>Session 1 Chairpersons: Dr. Balaji Jegannathan & Dr. Prabagar Manickam NGS interpretation of solid tumours - A Masterclass for the Modern Oncologist Speaker: Dr. Arun Seshachalam</p>	
11:20 am to 12:00 pm	<p>Cellular Therapy Workshop Part 1 Chairpersons: Dr. K Kalaichelvi, Dr. Rejiv Rajendranath & Dr. Sankar Srinivasan</p>	
11:20 - 11:40	Bispecific T Cell Engagers In Lymphoma	Dr. Rajkumar Ramasamy
11:40 - 12:00	Bispecific T Cell Engagers In Myeloma	Dr. Suresh Kumar B
12:00 pm to 12:40 pm	<p><i>Sponsored Session (BMS)</i></p>	
12:40 pm to 1:00 pm	<p><i>Sponsored Session (AstraZeneca)</i> Transforming patient outcomes with innovative therapy in advanced unresectable HCC Speaker - Dr. Bharath Rangarajan</p>	
1:00 pm to 1:20 pm	<p><i>Sponsored Session (Zydus)</i></p>	
1:20 pm to 1:40 pm	Lunch	
1:40 pm to 2:00 pm	<p><i>Sponsored Session (Zydus)</i></p>	
2:00 pm to 2:40 pm	<p>Cellular Therapy Workshop Part 2 Chairpersons: Dr. Krishna Kumar Rathnam & Dr. Bharath Rangarajan</p>	
2:00 - 2:20	CAR T-cell therapy - Patient preparation to toxicity Management	Dr. PK Jayachandran
2:20 - 2:40	CAR T-cell therapy - When to use it and What to Expect	Dr. Ram Abhinav K



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY

K M C H Koval Medical Center
and Hospital



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

2:40 pm to 3:00 pm	<p><i>Sponsored Session (ImmunoAct)</i> RWE of NexCAR19 in relapsed and refractory B- NHL Speaker - Dr. Suman Kalyan</p>	
3:00 pm to 4:00 pm	<p>Colorectal Cancer Chairpersons: Dr. Jegan Niwas, Dr. Raja G & Dr. N Sudhakar</p>	
3:00 - 3:06	Abstract 1 - Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer	Dr. Kumanan J
3:06 - 3:12	Abstract 2 - Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial	Dr. Teena Rajan
3:12 - 3:18	Abstract 3 - Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer - BREAKWATER Trial	Dr. Narendran K
3:20 - 4:00	<p>Panel Discussion Moderator: Dr. Bharath Rangarajan Panelists: Dr. Narmadha Rathinasamy, Dr. Uddiptya Goswami, Dr. Anand Praveen Kumar, Dr. Vidhya Ramalingam, Dr. Arthi Elango, Dr. Sankar Srinivasan, Dr. Priyanka Raju & Dr. Naveen K</p>	
4:00 pm to 4:20 pm	<p><i>Sponsored Session (MSD)</i> Role of Immunotherapy in 1st line R or M HNSCC Speaker: Dr. Kiran Kumar DVS</p>	
4:20 pm to 4:40 pm	<p><i>Sponsored Session (Roche)</i></p>	
4:40 pm to 5:00 pm	<p><i>Sponsored Session (MSD)</i> Shifting Paradigms in treatment of metastatic Renal Cell Carcinoma with Immunotherapy Speaker: Dr Bhavesh Poladia</p>	
5:00 pm to 5:30 pm	<p><i>Sponsored Session (Eli Lilly)</i> Panel Discussion on Identifying & Managing the High Risk HR+ HER2-Ve Node positive Early Breast Cancer Patients Moderator: Dr. S Krupa Shankar Panelists: Dr. Vijay G & Dr. Suresh Kumar B</p>	
8:00 pm onwards	<p>Dinner</p>	



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY



**Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

Day 2 | 21st March 2026 | Saturday | Hall A

8:30 am to 9:10 am	Prelims for Quiz Coordinator: Dr. Vijay G	
9:10 am to 9:30 am	<i>Sponsored Session (Glenmark)</i> Rationale to Practice: Tislelizumab in Esophageal Carcinoma Speaker - Dr. Krishnakumar Rathnam	
9:30 am to 10:50 am	Gynaecological Cancer Chairpersons: Dr. K Kalaichelvi, Dr. Venkatraman Radhakrishnan & Dr. Prasad Eswaran	
9:30 - 9:50	Practise changing ESGO/ESTRO/ESP 2023–2024	Dr. Anjana Joel
9:50 - 9:56	Abstract 1 - Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial	Dr. Nirmal Arasu
9:56 - 10:02	Abstract 2 - Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.	Dr. Madijagane R
10:02 - 10:08	Abstract 3 - Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial	Dr. Neelam Singh
10:10 - 10:50	Panel Discussion Moderator: Dr. S Krupa Shankar Panelists: Dr. Muthulingesh K, Dr. Arun Prasath N, Dr. Haridas Mani, Dr. Suresh Kumar B, Dr. Deepa Susan Joy Philip, Dr. S Gandhimathi, Dr. Ajoy Oommen John & Dr. Lingeshwaran Subburaj	
10:50 am to 11:50 am	Head & Neck Cancer Chairpersons: Dr. Suman Kalyan, Dr. V Arumugam & Dr. R Deivanayagam	
10:50 - 10:56	Abstract 1 - Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer - Keynote 689	Dr. Jerin J Ovet
10:56 - 11:02	Abstract 2 - NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.	Dr. Ashvin Jeberson Paul
11:02 - 11:08	Abstract 3 - Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo	Dr. N Kharthik



+91 93215 30354



tamos2026@gmail.com



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY



**Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

	(pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma	
11:10 - 11:50	Panel Discussion Moderator: Dr. Bhavesh Poladia Panelists: Dr. Kumanan J, Dr. Narendran K, Dr. Nirmal Arasu, Dr. Neelam Singh, Dr. Anand Praveen Kumar, Dr. Josh Thomas Georgy, Dr. Ajoy Oommen John & Dr. Vuriti Navya Manasa	
11:50 am to 12:20 pm	Inauguration	
12:20 pm to 1:20 pm	GBM	
1:20 pm to 2:00 pm	Lunch Break	
2:00 pm to 2:20 pm	<i>Sponsored Session (Johnson & Johnson)</i> A tale of 2 stories - redefining treatment outcomes with mariposa 2 & papillon Moderator - Dr. T Raja Panelists - Dr. Narendran K, Dr. Ramya Ananthakrishnan, Dr. Narmadha Rathinasamy, Dr. Sujith Kumar Mullapally, Dr. Vijay G & Dr. Sivakumar Kailasam	
2:20 pm to 3:20 pm	Lung Cancer Chairpersons: Dr. S G D Gangadaran, Dr. PN Sathiyamoorthy & Dr. B Sivanesan	
2:20 - 2:26	Abstract 1 - Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial	Dr. Karthikeyan Radhakrishnan
2:26 - 2:32	Abstract 2 - Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer	Dr. Narmadha Rathinasamy
2:32 - 2:38	Abstract 3 - Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy	Dr. Mangai Suseela M
2:40 - 3:20	Panel Discussion Moderator: Dr. Arun Seshachalam Panelists: Dr. Rajkumar Ramasamy, Dr. Indhuja MV, Dr. Vijaya Murugan, Dr. S Vinodh Kumar, Dr. Sujith Kumar Mullapally, Dr. S Kishore Kumar, Dr. Prasanna Rammohan & Dr. Arun Ramanan V	
3:20 pm to 3:40 pm	<i>Sponsored Session (Roche)</i>	
3:40 pm to 4:40 pm	Breast Cancer Chairpersons: Dr. S Lakshminarasimhan, Dr. Jeba Singh Joseph & Dr. David Praveen Kumar	
3:40 - 3:46	Abstract 1 - Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer; DESTINY-Breast05	Dr. Kiran Kumar DVS



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY

K M **C H** **Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

3:46 - 3:52	Abstract 2 - Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.	Dr. Satheesh Kumar D
3:52 - 3:58	Abstract 3 - PATINA trial: Phase III Trial of Palbociclib, Anti-HER2 Therapy, and Endocrine Therapy vs. Anti-HER2 Therapy and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer	Dr. Chodavarapu Dheeraj
4:00 - 4:40	Panel Discussion Moderator: Dr. T Raja Panelists: Dr. Anita Ramesh, Dr. Sivakumar Kailasam, Dr. Mangai Suseela M, Dr. N Vasanth Rooban, Dr. Kavi Shankar, Dr. Nandhakumar, Dr. Josh Thomas Georgy & Dr. Rajkumar Arumugam	
4:40 pm to 5:40 pm	Pancreaticobiliary Cancer Chairpersons: Dr. Rajasekaran PN, Dr. Joseph Dominic, Dr. Jegan Niwas & Dr. Anita Ramesh	
4:40 - 4:46	Abstract 1 - A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).	Dr. Karthic S
4:46 - 4:52	Abstract 2 - A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB study	Dr. Biju Azariah
4:52 - 4:58	Neoadjuvant FOLFIRINOX vs Neoadjuvant Gemcitabine based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2) : Multicentre, open label, phase 3 randomised trial	Dr. Kavi Shankar
5:00 - 5:40	Panel Discussion Moderator: Dr. Krishna Kumar Rathnam Panelists: Dr. Rajiv Gandhi, Dr. Ramya Ananthkrishnan, Dr. Niranjana Vijayaraghavan, Dr. Paari Vijayaragavan, Dr. Ramachandran Subramaniam, Dr. Sujith Kumar Mullanpally, Dr. Arun Ramanan V & Dr. M Vishwanath	
5:40 pm to 6:00 pm	<i>Sponsored Session (MSD)</i> Treatment Evolution of Non-squamous Non-small Cell Lung Cancer Speaker: Dr. Ramya Ananthkrishnan	
6:00 pm to 6:20 pm	<i>Sponsored Session (AstraZeneca)</i> HER2 Ultralow: An Emerging Frontier In Breast Cancer Treatment Speaker - Dr. T Raja	



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY

K M **C H** **Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

6:20 pm to 6:40 pm	<i>Sponsored Session (AstraZeneca)</i> Transforming the Unresectable Stage III NSCLC Landscape: From PACIFIC to LAURA Speaker - Dr. PK Jayachandran	
6:40 pm to 7:00 pm	AI in Healthcare	Dr. Purvish M Parikh
7:00 pm to 7:05 pm	Top 5 posters will be announced and they will be making an oral paper presentation on day 3	
8:00 pm onwards	Dinner	
Day 3 22nd March 2026 Sunday Hall A		
8:30 am to 10:00 am	TAMPOS Gold Medal Exam Coordinators: Dr. Krishna Kumar Rathnam, Dr. S Krupa Shankar, Dr. PK Jayachandran & Dr. Kiran Kumar DVS Examiners: Dr. PN Sathiyamoorthy, Dr. Prabagar Manickam, Dr. Venkatraman Radhakrishnan & Dr. J Kannan	
10:00 am to 10:20 am	<i>Sponsored Session (GSK)</i>	
10:20 am to 11:10 am	Hodgkin's Lymphoma Chairpersons: Dr. Durai Mavalavan, Dr. M Manickavasagam & Dr. J Kannan	
10:20 - 10:26	Abstract 1 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma - SWOG S1826	Dr. Deepan Rajamanickam
10:26 - 10:32	Abstract 2 - Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavourable Hodgkin Lymphoma: Final Analysis of the Randomised German Hodgkin Study Group Phase II NIVAHL Trial	Dr. Niranjan Vijayaraghavan
10:32 - 10:38	Abstract 3 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial	Dr. PK Jayachandran
10:40 - 11:10	Panel Discussion Moderator: Dr. Vijay G Panelists: Dr. Chandralekha Krishnan, Dr. Jerin J Ovet, Dr. Ramya Ananthakrishnan, Dr. Anbarasan Sekar, Dr. S Krupa Shankar, Dr. Karthikeyan Selvaraj, Dr. Muthulingesh K, Dr. Nithya Sridharan, Dr. Vino Anand S & Dr. Viji V Julian	
11:10 am to 12:00 pm	Multiple Myeloma Chairpersons: Dr. S Subramanian, Dr. Balaji Jegannathan & Dr. S Suresh	
11:10 - 11:16	Abstract 1 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma	Dr. Karthikeyan Selvaraj



TAMIL NADU
MEDICAL AND
PEDIATRIC
ONCOLOGIST
SOCIETY

K M **C H** **Kovai Medical Center
and Hospital**



**Tamil Nadu Medical &
Pediatric Oncologist Society
(TAMPOS) Conference**

20TH TO 22ND MARCH 2026 | LE MÉRIDIEN, COIMBATORE

11:16 - 11:22	Abstract 2 - Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial	Dr. Chandralekha Krishnan
11:22 - 11:28	Abstract 3 - Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3	Dr. Deenadayalan Theivasikamani
11:30 - 12:00	<p>Panel Discussion Moderator: Dr. Rajkumar Ramasamy Panelists: Dr. Deepan Rajamanickam, Dr. PK Jayachandran, Dr. Balambika Radhakrishna Gopinath, Dr. B Akila, Dr. Karthikeyan Radhakrishnan, Dr. Bharadhwaj K, Dr. Deenadayalan Theivasikamani & Dr. Vijay G</p>	
12:00 pm to 12:40 pm	Top 5 Posters - Oral Presentation	
12:40 pm to 1:00 pm	<i>Sponsored Session (Prime)</i>	
1:00 pm to 1:40 pm	Lunch	
1:40 pm to 2:00 pm	<i>Sponsored Session (Non Prime)</i>	
2:00 pm to 3:00 pm	Quiz Final Round & Valedictory Function Coordinator: Dr. Vijay G	
3:00 pm to 3:20 pm	<i>Sponsored Session (Non Prime)</i>	
3:20 pm to 3:40 pm	<i>Sponsored Session (Non Prime)</i>	
Day 2 21st March 2026 Saturday Board Room		
6:00 pm to 6:30 pm	ALK+ NSCLC Today and Tomorrow: Clinical Insights, Treatment Evolution and Innovation	